Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
ST. LOUIS--(BUSINESS WIRE)--Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that it has signed a research agreement with The Hamner Institutes for Health Sciences. Under this research agreement, Certara and The Hamner will explore the scientific benefits of using Certara’s Simcyp™ Simulator to drive hepatic drug exposure within The Hamner’s population-based, drug-induced liver injury (DILI) model. The partners plan to integrate The Hamner’s DILIsym® modeling software into Certara’s Simcyp Population-based Simulator and test the integrated product’s simulation capabilities with respect to drug exposure and resultant liver toxicity. Both of these systems are used by several leading international pharmaceutical companies.
Help employers find you! Check out all the jobs and post your resume.
